In vitro activities of candidate microbicides against cell-associated HIV

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 805-815

  Selhorst, Philippe ^a,b,c   Grupping, Katrijn ^a,b,c   Bourlet, Thomas ^d   Delézay, Olivier ^d   Ariën, Kevin K ^a   Vanham, Guido ^a,b,c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITÉ JEAN MONNET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DAPIVIRINE; ENFUVIRTIDE; FIREFLY LUCIFERASE; GAG PROTEIN; LOPINAVIR; M48 U1; MARAVIROC; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; RALTEGRAVIR; SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELL FREE SYSTEM; CELL LINE; COCULTURE; CONTROLLED STUDY; DRUG ACTIVITY; EFFECTOR CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MACROPHAGE; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TARGET CELL; VIRUS ENTRY; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; COCULTURE TECHNIQUES; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 84856075756     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05801-11     Document Type: Article

References (51)

1. Abela IA. 2011.The role of neutralizing antibodies in inhibition of cell-to-cell transmission, abstr 101.Abstr. Keystone Symp. HIV Evol., Genomics Pathog., Whistler, Canada.
2. Agosto LM, et al. 2007. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 368:60-72. (Pubitemid 47599558)
3. Allaway GP, et al. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retrovir. 11:533-539.
4. Anderson DJ, et al. 2010. Targeting Trojan Horse leukocytes for HIV prevention. AIDS 24:163-187.
5. Ariën KK, Jespers V, Vanham G. 2011. HIV sexual transmission and microbicides. Rev. Med. Virol. 21:110-133.
6. Balzarini J, Van Damme L. 2007. Microbicide drug candidates to prevent HIV infection. Lancet 369:787-797. (Pubitemid 46335821)
7. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D. 2007. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol. 71:3-11. (Pubitemid 46020972)
8. Beirnaert E, et al. 1998. Design and evaluation of an in-house HIV-1 (group M and O), SIVmnd and SIVcpz antigen capture assay. J. Virol. Methods 73:65-70. (Pubitemid 28473234)
9. Brouwers J, Vermeire K, Grammen C, Schols D, Augustijns P. 2011. Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: a case study with saquinavir. Antiviral Res. 91:217-223.
10. Buffa V, et al. 2009. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J. Gen. Virol. 90:234-243.
11. Burton DR, Barbas CF III. 1994. Human antibodies from combinatorial libraries. Adv. Immunol. 57:191-280.
12. Carr JM, Hocking H, Li P, Burrell CJ. 1999. Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology 265:319-329. (Pubitemid 30022226)
13. Chen P, Hubner W, Spinelli MA, Chen BK. 2007. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J. Virol. 81:12582-12595. (Pubitemid 350085872)
14. Chiba-Mizutani T, et al. 2007. Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to antihuman immunodeficiency virus type 1 drugs. J. Clin. Microbiol. 45:477-487.
15. Clotet-Codina I, et al. 2009. HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection. Antiviral Res. 83:94-98.
16. Coombs RW, Reichelderfer PS, Landay AL. 2003. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 17:455-480. (Pubitemid 36293099)
17. Dai J, et al. 2009. Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J. Virol. 83:4528-4537.
18. D'Cruz OJ, Uckun FM. 2006. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J. Antimicrob. Chemother. 57:411-423. (Pubitemid 43240192)
19. Evans A. 2010. Protease inhibitors darunavir, lopinavir and ritonavir as potential microbicides, abstr 24.Abstr. Int. Microbicides Conf.
20. Field HJ, De Clercq E. 2008. Antiviral Chemistry and Chemotherapy's current antiviral agents FactFile: DNA viruses. Antivir. Chem. Chemother. 19:51.
21. Gali Y, et al. 2010. Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. J. Virol. Methods 165:186-197.
22. Ganesh L, et al. 2004. Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J. Virol. 78: 11980-11987. (Pubitemid 39390783)
23. Gousset K, et al. 2008. Real-time visualization of HIV-1 GAG trafficking in infected macrophages. PLoS Pathog. 4:e1000015.
24. Groot F, Welsch S, Sattentau QJ. 2008. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 111:4660-4663.
25. Haase AT. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:217-223.
26. Ingallinella P, et al. 2009. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natil. Acad. Sci. U. S. A. 106:5801-5806.
27. Jolly C. 2010. T cell polarization at the virological synapse. Viruses 2:1261-1278.
28. Ketas TJ, et al. 2003. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J. Virol. 77:2762-2767. (Pubitemid 36222803)
29. Kreisberg JF, Yonemoto W, Greene WC. 2006. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 203:865-870.
30. Lederman MM, Offord RE, Hartley O. 2006. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6:371-382.
31. Margolis L, Shattock R. 2006. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat. Rev. Microbiol. 4:312-317.
32. Martin N, Sattentau Q. 2009. Cell-to-cell HIV-1 spread and its implications for immune evasion. Curr. Opin. HIV AIDS 4:143-149.
33. Martin N, et al. 2010. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J. Virol. 84:3516-3527.
34. Massanella M, et al. 2009. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 23:183-188.
35. Mori T, et al. 2005. Isolation and characterization of Griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 280:9345-9353. (Pubitemid 40409628)
36. Muratori C, Ruggiero E, Sistigu A, Bona R, Federico M. 2009. Human immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells. J. Gen. Virol. 90:2777-2787.
37. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH. 2002. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J. Virol. 76:10942-10950. (Pubitemid 35176211)
38. O'Keefe BR, et al. 2009. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl. Acad. Sci. U. S. A. 106:6099-6104.
39. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586. (Pubitemid 26097216)
40. Puigdomenech I, Massanella M, Cabrera C, Clotet B, Blanco J. 2009. On the steps of cell-to-cell HIV transmission between CD4 T cells. Retrovirology 6:89.
41. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
42. Sallé B, et al. 2010. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J. Infect. Dis. 202:337-344.
43. Sattentau Q. 2008. Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. Microbiol. 6:815-826.
44. Sherer NM, et al. 2007. Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat. Cell Biol. 9:310-315. (Pubitemid 46344610)
45. Smith RJ, Bodine EN, Wilson DP, Blower SM. 2005. Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS 19:413-421. (Pubitemid 40446188)
46. Sonza S, et al. 1996. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J. Virol. 70:3863-3869. (Pubitemid 26157366)
47. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. 2007. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J. Virol. 81:1000-1012. (Pubitemid 46067924)
48. Sowinski S, et al. 2008. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat. Cell Biol. 10:211-219. (Pubitemid 351194051)
49. Stefanidou M. 2010. Evaluation of saquinavir as a candidate microbicide compound in cellular and mucosal tissue models of HIV-1 infection, abstr 115.Abstr. Int. Microbicides Conf.
50. Terrazas-Aranda K, Van Herrewege Y, Lewi PJ, Van Roey J, Vanham G. 2007. In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection. Antivir. Chem. Chemother. 18:141-151. (Pubitemid 47167766)
51. Van Herrewege Y, et al. 2008. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J. Antimicrob. Chemother. 61:818-826.